Get the Stockscreener App
1.58
4.24%
-0.07
After Hours:
1.56
-0.02
-1.27%
Silexion Therapeutics Corp stock is traded at $1.58, with a volume of 26,610.
It is down -4.24% in the last 24 hours and down -25.47% over the past month.
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
See More
Previous Close:
$1.65
Open:
$1.68
24h Volume:
26,610
Relative Volume:
0.51
Market Cap:
$4.94M
Revenue:
-
Net Income/Loss:
$-17.85M
P/E Ratio:
-0.0426
EPS:
-37.0644
Net Cash Flow:
$-13.02M
1W Performance:
+4.64%
1M Performance:
-25.47%
6M Performance:
-78.21%
1Y Performance:
-92.20%
1-Day Range:
$1.55
$1.69
1-Week Range:
$1.55
$1.81
52-Week Range:
$1.51
$26.70
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
1.58 | 5.16M | 0 | -17.85M | -13.02M | -37.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Trading Recap: Will Silexion Therapeutics Corp Equity Warrant benefit from government policyQuarterly Trade Report & Short-Term High Return Strategies - baoquankhu1.vn
Analyst Downgrade: Can Silexion Therapeutics Corp be recession proofMarket Trend Summary & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Silexion Highlights SIL204 RNAi Pancreatic Cancer Program Progress - TipRanks
Silexion Therapeutics Corp Prepares Investor Presentation on SIL204 - TradingView
Jobs Data: What is ALBTs P E ratio telling us2025 Sector Review & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Swing Trade: What is the earnings history of Claritev Corporation2025 Big Picture & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Opening: Will Silexion Therapeutics Corp Equity Warrant benefit from government policyQuarterly Profit Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Gap Down: Can Silexion Therapeutics Corp be recession proofQuarterly Risk Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Can Silexion Therapeutics Corp sustain its profitabilityMarket Sentiment Review & Safe Entry Point Identification - mfd.ru
Risk Hedge: Can Spring Valley Acquisition Corp II Equity Warrant sustain its profitability2025 Biggest Moves & Reliable Entry Point Alerts - baoquankhu1.vn
Investment Review: Can Silexion Therapeutics Corp Equity Warrant expand its profit marginsQuarterly Performance Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Silexion shares skyrocket 400% after encouraging pancreatic cancer drug results - MSN
Growth Value: What is the implied volatility of Silexion Therapeutics Corp2025 Biggest Moves & High Win Rate Trade Alerts - baoquankhu1.vn
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit - manilatimes.net
Silexion Therapeutics to Participate in 7th RNAi-Based Therapeutics Summit Focused on Advancing SIL204 for Pancreatic Cancer - Quiver Quantitative
Will Silexion Therapeutics Corp benefit from geopolitical trendsSector ETF Performance & Free Double Digit Growth Tips - bollywoodhelpline.com
Retail Surge: Whats the RSI of Kirby Corporation stock2025 Price Action Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Silexion reports breakthrough in KRAS cancer therapy - MSN
Signal Recap: What is the PEG ratio of Silexion Therapeutics Corp Equity Warrant2025 Key Lessons & Detailed Earnings Play Strategies - baoquankhu1.vn
Is Silexion Therapeutics Corp a defensive stockAnalyst Upgrade & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Silexion stock jumps after toxicology studies show no systemic toxicity - MSN
Can Silexion Therapeutics Corp Equity Warrant stock sustain free cash flow growthJuly 2025 Opening Moves & Fast Gain Swing Alerts - ulpravda.ru
Why Silexion Therapeutics Corp Equity Warrant stock attracts high net worth investorsFit and Size Notes & quick comparison of popular models - Улправда
Can Silexion Therapeutics Corp Equity Warrant stock beat market expectations this quarterRecession Risk & Fast Exit Strategy with Risk Control - Улправда
Dividend Watch: Will Silexion Therapeutics Corp stock deliver strong dividend growthPortfolio Risk Summary & Fast Moving Market Watchlists - Улправда
Is Silexion Therapeutics Corp stock a buy for dividend growthJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - ulpravda.ru
Why retail investors favor Silexion Therapeutics Corp stockQuarterly Market Review & Free High Accuracy Swing Entry Alerts - ulpravda.ru
How strong is Silexion Therapeutics Corp stock revenue growthProduct Launch & Entry Point Confirmation Signals - Улправда
Will Silexion Therapeutics Corp stock deliver strong dividend growthPortfolio Risk Summary & Fast Moving Market Watchlists - Улправда
What momentum indicators show for Silexion Therapeutics Corp Equity Warrant stockMarket Performance Recap & Free Long-Term Investment Growth Plans - ulpravda.ru
Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Spike Watch & Daily Entry Point Trade Alerts - Улправда
Can Silexion Therapeutics Corp stock weather global recession2025 Price Action Summary & Short-Term High Return Strategies - Улправда
Signal Recap: What technical signals suggest for Silexion Therapeutics Corp stockWeekly Market Report & Consistent Growth Equity Picks - ulpravda.ru
Will Silexion Therapeutics Corp stock outperform Dow Jones indexTrade Entry Summary & Community Driven Trade Alerts - ulpravda.ru
Silexion Therapeutics CorpOrdinary Shares (NQ: SLXN - FinancialContent
Silexion outlines 2026 plans after transformational 2025 progress - TipRanks
Silexion Therapeutics Corp Highlights 2025 Achievements and 2026 Milestones - TradingView — Track All Markets
Silexion Therapeutics' Cancer Drug to Enter Human Trials in Early 2026 - marketscreener.com
Silexion Therapeutics Reports Promising Preclinical Results for SIL204 in KRAS-Driven Cancers and Plans Phase 2/3 Trial Initiation for 2026 - Quiver Quantitative
Silexion Therapeutics Releases CEO Letter to Shareholders - GlobeNewswire
Cash per share of Silexion Therapeutics Corp Warrant – NASDAQ:SLXNW - TradingView — Track All Markets
Merger Talk: Is Silexion Therapeutics Corp Equity Warrant stock trading at a premium valuation2025 Top Decliners & Daily Volume Surge Signals - Bộ Nội Vụ
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Risk Hedge: Will Silexion Therapeutics Corp stock deliver strong dividend growth2025 Market Overview & Safe Capital Growth Stock Tips - Bộ Nội Vụ
Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsJuly 2025 Retail & Free Technical Pattern Based Buy Signals - Улправда
Can Silexion Therapeutics Corp Equity Warrant stock hit record highs againJuly 2025 Weekly Recap & Daily Chart Pattern Signal Reports - Улправда
Will Silexion Therapeutics Corp Equity Warrant stock pay special dividendsTrade Exit Report & Weekly Top Performers Watchlists - DonanımHaber
How Silexion Therapeutics Corp stock compares to growth peersQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - DonanımHaber
Risk Analysis: Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsPortfolio Risk Report & High Conviction Trade Alerts - Улправда
Treasury Yields: How strong is Silexion Therapeutics Corp stock revenue growthWeekly Trade Report & AI Based Buy and Sell Signals - DonanımHaber
Silexion Therapeutics (NASDAQ:SLXN) Upgraded at Zacks Research - Defense World
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):